Adjunctive Study of AL-37807 Ophthalmic Suspension
Information source: Alcon Research
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Open-Angle Glaucoma; Ocular Hypertension
Intervention: AL-37807 ophthalmic suspension, 0.1% (Drug); Timolol gel forming solution, 0.5% (Drug); AL-37807 ophthalmic solution vehicle (Other); Latanoprost ophthalmic solution (Drug)
Phase: Phase 2
Status: Completed
Sponsored by: Alcon Research
Summary
The purpose of the study is to compare the safety and intraocular pressure-lowering efficacy
of AL-37807 ophthalmic suspension vs. Timolol gel forming solution vs. AL-37807 vehicle, all
dosed concomitantly with Xalatan, in patients with open-angle glaucoma or ocular
hypertension.
Clinical Details
Official title: Comparison of Safety and Efficacy of Al-37807 Ophthalmic Suspension vs. Timolol Gel Forming Solution and Vehicle, All Dosed Concomitantly With Xalatan in Patients With Open-Angle Glaucoma or Ocular Hypertension
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Primary outcome: Mean change from baseline in intraocular pressure
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Open-angle glaucoma
- Ocular hypertension
- Must have been on Xalatan for at least 3 months
- VA not worse than 0. 60
- Other protocol-defined inclusion criteria may apply
Exclusion Criteria:
- Age related
- Other protocol-defined exclusion criteria may apply
Locations and Contacts
Contact Alcon Call Center at 1-888-451-3937, Fort Worth, Texas 76134, United States
Additional Information
Starting date: November 2007
Last updated: December 3, 2012
|
